Septra and Hepatic neoplasm malignant recurrent - a phase IV clinical study of FDA data

Summary:

Hepatic neoplasm malignant recurrent is reported only by a few people who take Septra.

The phase IV clinical study analyzes which people take Septra and have Hepatic neoplasm malignant recurrent. It is created by eHealthMe based on reports of 8,806 people who have side effects while taking Septra from the FDA, and is updated regularly.

Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.

On Mar, 22, 2023

8,806 people reported to have side effects when taking Septra.
Among them, 4 people (0.05%) have Hepatic neoplasm malignant recurrent.

What is Septra?

Septra has active ingredients of sulfamethoxazole; trimethoprim. It is often used in urinary tract infection. eHealthMe is studying from 9,157 Septra users for its effectiveness, alternative drugs and more.

What is Hepatic neoplasm malignant recurrent?

Hepatic neoplasm malignant recurrent (liver cancer-recurrent) is found to be associated with 147 drugs and 73 conditions by eHealthMe.

Number of Septra and Hepatic neoplasm malignant recurrent reports submitted per year:

Could Septra cause Hepatic neoplasm malignant recurrent?

Gender of people who have Hepatic neoplasm malignant recurrent when taking Septra *:

female: 0.0 %
male: 100 %

Age of people who have Hepatic neoplasm malignant recurrent when taking Septra *:

Common drugs people take besides Septra *:

Valcyte: 4 people, 100.00%
Prograf: 4 people, 100.00%
Nexium: 4 people, 100.00%
Mycophenolate Mofetil: 4 people, 100.00%
Prednisolone Acetate: 3 people, 75.00%
Aspirin: 2 people, 50.00%

Common side effects people have besides Hepatic neoplasm malignant recurrent *:

Pleural Effusion (water on the lungs): 2 people, 50.00%
Lymph Follicular Hypertrophy (an increase in the size of the lymph node follicles): 2 people, 50.00%
Lung Neoplasm (tumour of lung): 2 people, 50.00%
Fractured Sacrum: 2 people, 50.00%
Collapse Of Lung (functional breakdown of lung): 2 people, 50.00%
Ascites (accumulation of fluid in the abdominal cavity): 2 people, 50.00%
Tumor: 1 person, 25.00%
Pulmonary Oedema (fluid accumulation in the lungs): 1 person, 25.00%
Pneumonia Primary Atypical (primary atypical pneumonia which were probably caused by mycoplasma pneumoniae): 1 person, 25.00%
Pneumonia: 1 person, 25.00%

* Approximation only. Some reports may have incomplete information.

Do you take Septra and have Hepatic neoplasm malignant recurrent?

Check whether Hepatic neoplasm malignant recurrent is associated with a drug or a condition

How to use the study?

You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.

Related studies

How severe was Hepatic neoplasm malignant recurrent and when was it recovered:

Hepatic neoplasm malignant recurrent in Septra

Expand to all the drugs that have ingredients of sulfamethoxazole; trimethoprim:

Hepatic neoplasm malignant recurrent and drugs with ingredients of sulfamethoxazole; trimethoprim

Alternative drugs to, pros and cons of Septra:

Septra (9,157 reports)

Common Septra side effects:

Breathing difficulty: 799 reports
Fever: 792 reports
Fatigue (feeling of tiredness): 777 reports
Rashes (redness): 693 reports
Pain: 639 reports
Pneumonia: 577 reports

Browse all side effects of Septra:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Hepatic neoplasm malignant recurrent treatments and more:

Hepatic neoplasm malignant recurrent (308 reports)

COVID vaccines that are related to Hepatic neoplasm malignant recurrent:

All the drugs that are associated with Hepatic neoplasm malignant recurrent:

Hepatic neoplasm malignant recurrent (147 drugs)

All the conditions that are associated with Hepatic neoplasm malignant recurrent:

Hepatic neoplasm malignant recurrent (73 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on sulfamethoxazole; trimethoprim (the active ingredients of Septra) and Septra (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.